Worries About Discontinuing Buprenorphine Treatment: Scale Development and Clinical Correlates
- 16 April 2019
- journal article
- research article
- Published by Wiley in The American Journal on Addictions
- Vol. 28 (4) , 270-276
Abstract
Background and Objectives: Despite the benefits of maintenance buprenorphine treatment for opioid use disorder (OUD), many individuals report an interest in discontinuing the medication, while also expressing worries about tapering. The purpose of this study was to develop a measure of worries about buprenorphine discontinuation (“Off Bupe”) and determine the demographic and clinical characteristics associated with these worries.Methods: Between May 2017 and May 2018, we surveyed adults in an outpatient primary care buprenorphine program (n = 138). Reliability and validity of the Off Bupe measure were examined.Results: Participants averaged 39 years of age, 54% were male, average duration of buprenorphine was 189 weeks and 85.5% reported eventually wanting to discontinue buprenorphine, although fewer than 10% were actively tapering. We derived two scales, withdrawal symptom worry (10 items, ɑ = 0.94) and relapse worry (7 items, ɑ = 0.88). Worry about symptoms was positively associated with current buprenorphine dose (P = 0.016), physical discomfort avoidance (P < 0.001), and inversely associated with self‐efficacy to quit buprenorphine (P < 0.001) and distress tolerance (P < 0.001). Worry about opioid relapse was associated positively with age (P = 0.019), current buprenorphine dose (P = 0.004), physical discomfort avoidance (P < 0.001), and impulsivity (P = 0.002), and inversely associated with self‐efficacy to quit buprenorphine (P < 0.001).Discussion and Conclusions: Psychometric evaluation of the “Off Bupe” scale demonstrated its content and construct validity and internal reliability.Scientific Significance: The scale might help individuals with OUD and their providers identify concerns about discontinuing buprenorphine. (Am J Addict 2019;28:270–276)Keywords
Funding Information
- National Institute on Drug Abuse (R21 DA041153)
This publication has 40 references indexed in Scilit:
- The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: A reviewDrug and Alcohol Dependence, 2011
- Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implicationsNature Reviews Neuroscience, 2011
- Improved Quality of Life, Clinical, and Psychosocial Outcomes Among Heroin-dependent Patients on Ambulatory Buprenorphine MaintenanceSubstance Use & Misuse, 2009
- Buprenorphine tapering schedule and illicit opioid useAddiction, 2009
- Cost analysis of clinic and office-based treatment of opioid dependence: Results with methadone and buprenorphine in clinically stable patientsDrug and Alcohol Dependence, 2009
- Discomfort intolerance: Development of a construct and measure relevant to panic disorderJournal of Anxiety Disorders, 2006
- What are drug users looking for when they contact drug services: abstinence or harm reduction?Drugs: Education, Prevention and Policy, 2004
- Psychiatric Aspects of ImpulsivityAmerican Journal of Psychiatry, 2001
- Substance Use, Injury, and Risk‐Taking Dispositions in the General PopulationAlcohol, Clinical and Experimental Research, 1999
- Research Note: Abstinence Fear in Methadone Maintenance Withdrawal: A Possible Obstacle for Getting off MethadoneSubstance Use & Misuse, 1997